Impact of cancer therapies on ovarian reserve

Measures of ovarian reserve are impaired among cancer survivors compared with unexposed females of similar age. The degree of impairment is dependent on the toxicity of the previous treatment.

0
0
Upvote 0 Comment

Authors

Clarisa R. Gracia, M.D., M.S.C.E., Mary D. Sammel, Sc.D., Ellen Freeman, Ph.D., Maureen Prewitt, R.N., Claire Carlson, R.N., Anushree Ray, Ashley Vance, Jill P. Ginsberg, M.D.

Volume 97, Issue 1 , Pages 134-140.e1

Abstract

Objective:

To determine whether measures of ovarian reserve differ between females exposed to cancer therapies in a dose-dependent manner as compared with healthy controls of similar age and late reproductive age.

Design:

Cross-sectional analysis of data from a prospective cohort study.

Setting:

University medical center.

Patient(s):

Seventy-one cancer survivors aged 15–39 years; 67 healthy, similarly aged unexposed subjects; and 69 regularly menstruating women of late reproductive age (40–52 years).

Intervention(s):

None.

Main Outcome Measure(s):

Early follicular-phase hormones (FSH, E2, inhibin B, antimüllerian hormone [AMH]) and ovarian ultrasound measurements (ovarian volume and antral follicle counts [AFC]) were compared using multivariable linear regression.

Result(s):

In adjusted models, FSH, AMH, and AFC differed between exposed vs. unexposed subjects (FSH 11.12 mIU/mL vs. 7.25 mIU/mL; AMH 0.81 ng/mL vs. 2.85 ng/mL; AFC 14.55 vs. 27.20). In participants with an FSH

Conclusion(s):

Measures of ovarian reserve are impaired in a dose-dependent manner among cancer survivors compared with unexposed females of similar age. Reproductive hormone levels in menstruating survivors exposed to high-dose therapy are similar to those in late-reproductive-age women. The predictive value of measures for pregnancy and menopause must be studied.

ClinicalTrials.gov identifier:

NCT01143844.

Read full text on: http://www.fertstert.org/article/S0015-0282(11)02725-7/fulltext

Go to the profile of Fertility and Sterility

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.

No comments yet.